

SPEAKER 1: Certainly, one would imagine that the world isn't simply divided into you have or you don't have diabetes. You have a high LDL cholesterol or not. Those are simple subgroup analysis.

Probably the best way to get an adequate assessment of the true individual risk of a patient is to look at the constellation of high-risk features. And of course, for example, one would assume those with diabetes with a particular high level of LDL cholesterol with a prior coronary artery bypass grafting surgery or previous event, that just elevates even further a patient with diabetes, for example, their baseline risk. And so the relative benefit will be consistent across all of those types of high-risk characteristics. But the absolute benefit with therapy with PCSK9 inhibition will be more magnified in those people that have a constellation of multiple risk features.